Literature DB >> 7656910

Prognostic significance of incidental renal cell carcinoma.

D Bretheau1, E Lechevallier, C Eghazarian, V Grisoni, C Coulange.   

Abstract

From 1980 to 1991, 236 patients with renal cell carcinoma were treated in our department. We studied the characteristics and the prognostic significance of 74 patients with incidental renal cancer in comparison with those with symptomatic tumors. The mean age of the patients was 59.8 years and the sex ratio 2 males/1 female. The incidence of incidental tumors increased from 14% in 1980 to 48% in 1991. Incidental tumors were discovered mainly during examination for cardiovascular diseases (26%), hepatobiliary diseases (22%) and general health examination (23%). Local tumoral stage and histologic grade were significantly lower for the incidental tumors than for symptomatic ones (p = 0.002 and p = 0.001). In the same way, the rates of the patients with metastases or nodal involvement were lower for those with incidental tumors than for those with symptomatic tumors (p = 0.008 and p = 0.001). The mean tumoral size was 5.7 +/- 3 cm for incidental tumors and 7.6 +/- 3.5 cm for symptomatic tumors (p = 0.0001). The survival was significantly different according to the circumstances of detection of the tumors (p < 0.001); the 5- and 10-year actuarial survival rates was 85% for the patients with incidental tumors and respectively 61 and 44% for the patients with symptomatic tumors. The multivariate analysis by Cox proportional hazard model showed three important and independent prognostic factors: the presence of metastases (relative risk (RR): 6.7), nodal involvement (RR: 4.6) and symptomatic tumors (RR: 1.7). The patients with incidental tumors had a better prognosis than those with symptomatic tumors because of lower tumoral size and local stage. The early diagnosis of renal cell carcinoma improved the prognosis of the patients.

Entities:  

Mesh:

Year:  1995        PMID: 7656910     DOI: 10.1159/000475189

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  14 in total

Review 1.  Immunotherapy in metastatic renal cell carcinoma.

Authors:  Karl Rohrmann; Michael Staehler; Nikolas Haseke; Alexander Bachmann; Christian G Stief; Michael Siebels
Journal:  World J Urol       Date:  2005-04-02       Impact factor: 4.226

2.  Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival.

Authors:  Helen Shi Stafford; Sidney L Saltzstein; Suzuho Shimasaki; Catherine Sanders; Tracy M Downs; Georgia Robins Sadler
Journal:  J Urol       Date:  2008-03-17       Impact factor: 7.450

3.  Renal cell carcinoma with solitary metastases appearing during 18 years of follow-up.

Authors:  M Siekierska-Hellmann; K Sworczak; A Lewczuk; K Błaut; E Boj
Journal:  Postgrad Med J       Date:  1997-09       Impact factor: 2.401

4.  Prognostic index of renal carcinomas.

Authors:  D L Répássy
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

5.  Disparities in the treatment of patients with IL-2 for metastatic renal cell carcinoma.

Authors:  Christopher S Saigal; Christopher M Deibert; Julie Lai; Matthias Schonlau
Journal:  Urol Oncol       Date:  2008-12-12       Impact factor: 3.498

6.  Robotic-assisted transperitoneal nephron-sparing surgery for small renal masses with associated surgical procedures: surgical technique and preliminary experience.

Authors:  Graziano Ceccarelli; Massimo Codacci-Pisanelli; Alberto Patriti; Cecilia Ceribelli; Alessia Biancafarina; Luciano Casciola
Journal:  Updates Surg       Date:  2013-04-26

7.  A commentary on "risk factors for renal cell cancer in a Japanese population".

Authors:  Esther Uña Cidon
Journal:  Clin Med Oncol       Date:  2009-08-14

Review 8.  Watchful waiting for small renal masses.

Authors:  Kamal Mattar; Michael A S Jewett
Journal:  Curr Urol Rep       Date:  2008-01       Impact factor: 3.092

9.  Renal cell carcinoma: Impact of mode of detection on its pathological characteristics.

Authors:  Paresh Jain; R Surdas; Pallavi Aga; Manoj Jain; Rakesh Kapoor; Aneesh Srivastava; Anil Mandhani
Journal:  Indian J Urol       Date:  2009 Oct-Dec

Review 10.  Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal.

Authors:  Mary Kilonzo; Jenni Hislop; Andrew Elders; Cynthia Fraser; Donald Bissett; Samuel McClinton; Graham Mowatt; Luke Vale
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.